Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 14C | Carbon-14 |
| 1L | First line |
| 1LOT | First line of therapy |
| 2L | Second line |
| 2LOT | Second line of therapy |
| 3L | Third line |
| 3LOT | Third line of therapy |
| 5-FU | Fluorouracil |
| 5-FU/LV | Fluorouracil and leucovorin |
| 5FU | Fluorouracil |
| ABC | Advanced biliary cancer |
| ABC-06 | Advanced Biliary Cancer 06 trial |
| ABCB1 | ATP-binding cassette subfamily B member 1 (P-glycoprotein) |
| ABCG2 | ATP-binding cassette subfamily G member 2 (breast cancer resistance protein) |
| ADC | Antibody-drug conjugate |
| AE | Adverse event |
| AHCYL1 | Adenosylhomocysteinase like 1 |
| AHFS | American Hospital Formulary Service |
| aHR | Adjusted hazard ratio |
| AJCC | American Joint Committee on Cancer |
| AKT | Protein kinase B |
| ALK | Anaplastic lymphoma kinase |
| ANOVA | Analysis of variance |
| ARID1 | AT-rich interaction domain 1 |
| ARID1A | AT-rich interaction domain 1A |
| ASC | Active symptom control |
| ASCO | American Society of Clinical Oncology |
| ATC | Anatomical Therapeutic Chemical classification |
| ATM | Ataxia telangiectasia mutated |
| ATP | Adenosine triphosphate |
| AUC | Area under the concentration-time curve |
| AUC0-inf | Area under the concentration-time curve from time zero to infinity |
| B+T | BGJ398 plus trametinib |
| BAIAP2L1 | BAR/IMD domain containing adaptor protein 2 like 1 |
| BAP1 | BRCA1-associated protein 1 |
| BCRP | Breast cancer resistance protein |
| BGJ398 | Development code for infigratinib |
| BICC1 | BicC family RNA binding protein 1 |
| BICR | Blinded independent central review |
| BID | Twice daily |
| BMI | Body mass index |
| BRAF | B-Raf proto-oncogene, serine/threonine kinase |
| BSEP | Bile salt export pump |
| BTC | Biliary tract cancer |
| BTT | Biliary tract tumor |
| C13D1 | Cycle 13, day 1 |
| C3D1 | Cycle 3, day 1 |
| CA 19-9 | Carbohydrate antigen 19-9 |
| CA19-9 | Carbohydrate antigen 19-9 |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CAFs | Cancer-associated fibroblasts |
| CAP | College of American Pathologists |
| CCA | Cholangiocarcinoma |
| CCDC6 | Coiled-coil domain containing 6 |
| CDA-AMC | Canada's Drug Agency |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CDKN2B | Cyclin-dependent kinase inhibitor 2B |
| CDx | Companion diagnostic |
| CEA | Carcinoembryonic antigen |
| cfDNA | Cell-free DNA |
| CFR | Code of Federal Regulations |
| CGP | Comprehensive genomic profiling |
| ChT | Chemotherapy |
| CI | Confidence interval |
| CLcr | Creatinine clearance |
| CLIA | Clinical Laboratory Improvement Amendments |
| Cmax | Maximum plasma concentration |
| CNS | Central nervous system |
| CR | Complete response |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| ctDNA | Circulating tumor DNA |
| CTNNB1 | Catenin beta 1 |
| CUP | Cancer of unknown primary |
| CYP | Cytochrome P450 |
| CYP1A2 | Cytochrome P450 1A2 |
| CYP2B6 | Cytochrome P450 2B6 |
| CYP2C19 | Cytochrome P450 2C19 |
| CYP2C8 | Cytochrome P450 2C8 |
| CYP2C9 | Cytochrome P450 2C9 |
| CYP2D6 | Cytochrome P450 2D6 |
| CYP2J2 | Cytochrome P450 2J2 |
| CYP3A | Cytochrome P450 3A |
| CYP3A4 | Cytochrome P450 3A4 |
| Cys491 | Cysteine 491 |
| d/pCCA | Distal or perihilar cholangiocarcinoma |
| dCCA | Distal cholangiocarcinoma |
| DCR | Disease control rate |
| Debio1347 | Development code for zoligratinib |
| DFS | Disease-free survival |
| dMMR | Mismatch repair deficient |
| DNA | Deoxyribonucleic acid |
| DOR | Duration of response |
| DoR | Duration of response |
| EAG | External assessment group |
| eAPC | Estimated annual percent change |
| ECC | Extrahepatic cholangiocarcinoma |
| eCCA | Extrahepatic cholangiocarcinoma |
| ECG | Electrocardiogram |
| ECM | Extracellular matrix |
| ECOG | Eastern Cooperative Oncology Group |
| EFS | Event-free survival |
| EGF | Epidermal growth factor |
| EGFR | Epidermal growth factor receptor |
| ELE-4008-202 | Protocol identifier of the ReFocus202 study |
| eLTS | Extended long-term survivors |
| EMA | European Medicines Agency |
| EMP | Extended molecular profiling |
| EORTC | European Organisation for Research and Treatment of Cancer |
| ePoster | Electronic poster |
| EQ-5D | EuroQol 5 Dimension |
| EQ-5D-5L | EuroQol 5 Dimension, 5 level version |
| ERBB | Erythroblastic oncogene B |
| ERBB2 | Erb-b2 receptor tyrosine kinase 2 |
| ERC | Endoscopic retrograde cholangiography |
| ERCP | Endoscopic retrograde cholangiopancreatography |
| ERK | Extracellular signal-regulated kinase |
| ESCAT | ESMO Scale for Clinical Actionability of Molecular Targets |
| ESMO | European Society for Medical Oncology |
| ESMO-MCBS | European Society for Medical Oncology Magnitude of Clinical Benefit Scale |
| ET | Eastern Time |
| EU | European Union |
| EUS | Endoscopic ultrasonography |
| evNGS | Externally validated next-generation sequencing |
| F-TKI | FGFR-specific tyrosine kinase inhibitor |
| f/r | Fusion or rearrangement |
| F1CDx | FoundationOne CDx |
| FDA | US Food and Drug Administration |
| FDG-PET | Fluorodeoxyglucose positron emission tomography |
| FF | FGFR2 fusion |
| FGF | Fibroblast growth factor |
| FGFR | Fibroblast growth factor receptor |
| FGFR1 | Fibroblast growth factor receptor 1 |
| FGFR2 | Fibroblast growth factor receptor 2 |
| FGFR3 | Fibroblast growth factor receptor 3 |
| FGFR4 | Fibroblast growth factor receptor 4 |
| FGFRi | Fibroblast growth factor receptor inhibitor |
| FIGHT-202 | Phase 2 trial of pemigatinib in previously treated cholangiocarcinoma |
| FIH | First-in-human |
| FISH | Fluorescence in situ hybridization |
| FNA | Fine-needle aspiration |
| FOENIX-CCA2 | Phase 2 trial of futibatinib in FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma |
| FOLFOX | Folinic acid, fluorouracil, and oxaliplatin |
| FR | Fold-reversal |
| FUDR | Floxuridine |
| GA | Genetic aberration |
| GBC | Gallbladder cancer |
| GemCis | Gemcitabine and cisplatin |
| GHS | Global health status |
| HAIP | Hepatic artery infusion pump |
| HBV | Hepatitis B virus |
| HCC | Hepatocellular carcinoma |
| HCRU | Healthcare resource utilization |
| HCV | Hepatitis C virus |
| HEK293 | Human embryonic kidney 293 cells |
| HER2 | Human epidermal growth factor receptor 2 |
| HLB | HLB Co., Ltd., majority owner of Elevar Therapeutics |
| HR | Hazard ratio; hormone receptor where written HR+ |
| IC50 | Half-maximal inhibitory concentration |
| ICC | Intrahepatic cholangiocarcinoma |
| iCCA | Intrahepatic cholangiocarcinoma |
| ICER | Incremental cost-effectiveness ratio |
| IDH1 | Isocitrate dehydrogenase 1 |
| IDH2 | Isocitrate dehydrogenase 2 |
| IHC | Immunohistochemistry |
| IHCC | Intrahepatic cholangiocarcinoma |
| IL-1β | Interleukin 1 beta |
| IND | Investigational new drug application |
| INHB | Incremental net health benefit |
| INMB | Incremental net monetary benefit |
| IPNB | Intraductal papillary neoplasm of the bile duct |
| IQR | Interquartile range |
| IRC | Independent review committee |
| IRR | Incidence rate ratio |
| IV | Intravenous |
| KEYNOTE-966 | Phase 3 trial of pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer |
| KM | Kaplan-Meier |
| KRAS | Kirsten rat sarcoma viral oncogene homolog |
| LBx | Liquid biopsy |
| LDP | Limited-duration prevalence |
| LLC | Limited liability company |
| LoE | Level of evidence |
| LOT | Line of therapy |
| LSM | Least squares mean |
| LV | Leucovorin |
| LY | Life-year |
| MAIC | Matching-adjusted indirect comparison |
| MAPK | Mitogen-activated protein kinase |
| MATE1 | Multidrug and toxin extrusion protein 1 |
| MATE2-K | Multidrug and toxin extrusion protein 2-K |
| MBq | Megabecquerel |
| Mbx | Metastatic-site biopsy |
| MCBS | Magnitude of Clinical Benefit Scale |
| MDTB | Multidisciplinary tumor board |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MEK | Mitogen-activated protein kinase kinase |
| MEK5 | Mitogen-activated protein kinase kinase 5 |
| mFOLFOX | Modified folinic acid, fluorouracil, and oxaliplatin |
| MKNK2 | MAPK interacting serine/threonine kinase 2 |
| mos | Months |
| mOS | Median overall survival |
| MRCP | Magnetic resonance cholangiopancreatography |
| MRI | Magnetic resonance imaging |
| MSI-H | Microsatellite instability-high |
| MTD | Maximum tolerated dose |
| mTOR | Mechanistic target of rapamycin |
| MYC | MYC proto-oncogene |
| N/A | Not applicable |
| NAFLD | Non-alcoholic fatty liver disease |
| nal-IRI | Liposomal irinotecan |
| NALIRICC | Randomized phase 2 trial of liposomal irinotecan with fluorouracil and leucovorin in biliary tract cancer |
| NC | Not calculable |
| NCCN | National Comprehensive Cancer Network |
| NDA | New drug application |
| NDC | National Drug Code |
| NE | Not estimable |
| NGS | Next-generation sequencing |
| NHI | National Health Insurance (Taiwan) |
| NHIA | National Health Insurance Administration (Taiwan) |
| NHIRD | National Health Insurance Research Database (Taiwan) |
| NHS | National Health Service |
| NICE | National Institute for Health and Care Excellence |
| NIFTY | Randomized phase 2b trial of liposomal irinotecan with fluorouracil and leucovorin in biliary tract cancer |
| NOS | Not otherwise specified |
| NR | Not reached |
| NT$ | New Taiwan dollar |
| NTRK | Neurotrophic tyrosine receptor kinase |
| OAT1 | Organic anion transporter 1 |
| OAT3 | Organic anion transporter 3 |
| OATP1B1 | Organic anion transporting polypeptide 1B1 |
| OATP1B3 | Organic anion transporting polypeptide 1B3 |
| OCT | Optical coherence tomography |
| OCT1 | Organic cation transporter 1 |
| OCT2 | Organic cation transporter 2 |
| OR | Odds ratio |
| ORR | Objective response rate |
| OS | Overall survival |
| P-gp | P-glycoprotein |
| pan-FGFRi | Inhibitor of all fibroblast growth factor receptor isoforms |
| PBRM1 | Polybromo 1 |
| Pbx | Primary tumor biopsy |
| pCCA | Perihilar cholangiocarcinoma |
| pCODR | pan-Canadian Oncology Drug Review |
| PD | Progressive disease |
| PD-L1 | Programmed death-ligand 1 |
| PDGF | Platelet-derived growth factor |
| PDy | Pharmacodynamics |
| pERC | pCODR Expert Review Committee |
| pERK | Phosphorylated extracellular signal-regulated kinase |
| PF | Progression-free |
| pFGFR | Phosphorylated fibroblast growth factor receptor |
| pFGFR2 | Phosphorylated fibroblast growth factor receptor 2 |
| PFS | Progression-free survival |
| PhA | Pheophorbide A |
| PI3K | Phosphoinositide 3-kinase |
| PK | Pharmacokinetics |
| PPE | Palmar-plantar erythrodysesthesia |
| PPPM | Per patient per month |
| PR | Partial response |
| PRKCA | Protein kinase C alpha |
| PRKCB | Protein kinase C beta |
| PRO | Patient-reported outcome |
| PROOF 301 | Phase 3 confirmatory trial of infigratinib in first-line FGFR2 fusion-positive cholangiocarcinoma |
| PS | Performance status |
| PSA | Probabilistic sensitivity analysis |
| PSM | Partitioned survival model |
| PTC | Percutaneous transhepatic cholangiography |
| PTEN | Phosphatase and tensin homolog |
| pts | Patients |
| Q4 | Fourth quarter of a calendar year |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| QDC | Once daily, continuous |
| QDD | Once daily, discontinuous |
| QLQ-BIL21 | EORTC Quality of Life Questionnaire, Cholangiocarcinoma and Gallbladder Cancer Module, 21 items |
| QLQ-C30 | EORTC Quality of Life Questionnaire Core 30 |
| QoL | Quality of life |
| QTc | QT interval corrected for heart rate |
| QTcF | QT interval corrected for heart rate by Fridericia's formula |
| RAF | Rapidly accelerated fibrosarcoma kinase |
| RAS | Rat sarcoma virus GTPase |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RET | Ret proto-oncogene |
| RFS | Relapse-free survival |
| RLY-4008 | Development code for lirafugratinib used by Relay Therapeutics |
| RLY-4008-101 | Protocol number of the ReFocus trial |
| RNA | Ribonucleic acid |
| ROS1 | ROS proto-oncogene 1, receptor tyrosine kinase |
| RP2D | Recommended phase 2 dose |
| RPED | Retinal pigment epithelial detachment |
| RT-PCR | Reverse transcription polymerase chain reaction |
| RTK | Receptor tyrosine kinase |
| RTOR | Real-Time Oncology Review |
| rwPFS | Real-world progression-free survival |
| S-1 | Tegafur, gimeracil, and oteracil |
| SAT | Subsequent anticancer therapy |
| SBRT | Stereotactic body radiotherapy |
| SD | Stable disease; standard deviation |
| SDF1 | Stromal cell-derived factor 1 |
| SEER | Surveillance, Epidemiology, and End Results |
| SMAD4 | SMAD family member 4 |
| SN-38 | 7-Ethyl-10-hydroxycamptothecin, the active metabolite of irinotecan |
| SoC | Standard of care |
| STAT3 | Signal transducer and activator of transcription 3 |
| t1/2 | Half-life |
| TA1005 | NICE technology appraisal guidance 1005 |
| TA1153 | NICE technology appraisal guidance 1153 |
| TA722 | NICE technology appraisal guidance 722 |
| TACC2 | Transforming acidic coiled-coil containing protein 2 |
| TACC3 | Transforming acidic coiled-coil containing protein 3 |
| TAP | Tumor area positivity |
| TAS-120 | Development code for futibatinib |
| TEAE | Treatment-emergent adverse event |
| TF | Tumor fraction |
| TKD | Tyrosine kinase domain |
| TKI | Tyrosine kinase inhibitor |
| Tmax | Time to maximum plasma concentration |
| TME | Tumor microenvironment |
| TNF | Tumor necrosis factor |
| TNM | Tumor, node, metastasis |
| TOPAZ-1 | Phase 3 trial of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer |
| TP53 | Tumor protein p53 |
| TR | Total radioactivity |
| TRAE | Treatment-related adverse event |
| TSG | Tumor suppressor gene |
| TTD | Time to deterioration |
| TTP | Time to progression |
| TWD | New Taiwan dollar |
| UK | United Kingdom |
| US | United States |
| US$ | United States dollar |
| USA | United States of America |
| USD | United States dollar |
| UV | Ultraviolet |
| VAS | Visual analogue scale |
| VAT | Value-added tax |
| VEGF | Vascular endothelial growth factor |
| VEGF-A | Vascular endothelial growth factor A |
| VEGF-C | Vascular endothelial growth factor C |
| WHO | World Health Organization |
| wk | Week |
| wks | Weeks |
| WNT | Wingless-related integration site |
| WT | Wild type |
| WTP | Willingness to pay |
| ZIP | Zone Improvement Plan (United States postal code) |